Search

Displaying results 1621 - 1630 of 3020 in total
  1. Drug

    Odesivimab

    go.drugbank.com/drugs/DB15900
    ApprovedInvestigational

    INMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320]

  2. Drug

    Macadamia seed oil glycereth-8 esters

    go.drugbank.com/drugs/DB14318
    Investigational

    Macadamia seed oil glycereth-8 esters is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  3. Drug

    Luspatercept

    go.drugbank.com/drugs/DB12281
    ApprovedInvestigational

    Luspatercept is a recombinant fusion protein comprised of a modified extracellular domain of activin receptor type IIB fused to the FC domain of human IgG1. It was first approved for use in the United States in November 2019 under the br...

  4. Drug

    Magnesium silicate

    go.drugbank.com/drugs/DB13249
    ApprovedWithdrawn

    [L2603] Under the FDA, magnesium silicate is determined as a member of the substances generally recognized as safe (GRAS) to be used as an anticaking agent.[L2605]

    Mixtures: Formula EC
  5. Drug

    Lemborexant

    go.drugbank.com/drugs/DB11951
    ApprovedInvestigational

    [A189006] This novel mechanism of action offers potential advantages over classic hypnotic agents, including a more favorable adverse effect profile and potentially greater efficacy, and may signal the

  6. Drug

    Ublituximab

    go.drugbank.com/drugs/DB11850
    ApprovedInvestigational

    [A241045] In December 2022, ublituximab was approved by the US FDA for the treatment of relapsing forms of multiple sclerosis, becoming the first and only anti-CD20 monoclonal antibody for multiple sclerosis

  7. Drug

    Atoltivimab

    go.drugbank.com/drugs/DB15898
    ApprovedInvestigational

    INMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320]

  8. Drug

    Natalizumab

    go.drugbank.com/drugs/DB00108
    ApprovedInvestigational

    In 2006, the FDA reintroduced the drug to the market for multiple sclerosis.[A261326] Natalizumab was further approved by the FDA for the treatment of Crohn's Disease in January 2008. … [A261331] On August 24, 2023, the first biosimilar to natalizumab, natalizumab-sztn, was approved by the FDA.[L48041] Natalizumab was approved by the European Commission on September 22, 2023.

  9. Drug

    NUC B1000

    go.drugbank.com/drugs/DB05242
    Experimental

    NUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct designed to produce four short interfering RNA (siRNA) molecules, formulated with a proprietary cationic-lipid delivery system. eiRNA ...

  10. Drug

    PL-3994

    go.drugbank.com/drugs/DB15355
    Investigational

    PL-3994 is under investigation in clinical trial NCT01304628 (Cross-Over Study of Subcutaneous Study Drug for the Treatment of Patients With Mild to Moderate Asthma).